Abstract P34

February 2014 in “ Plastic and Reconstructive Surgery ”

Lukas W. Pfannenstiel, Brian T. Maybruck, Brian Gastman

Studysummary This abstract provides no new research findings; it appears to be text related to the American Society of Plastic Surgeons' educational resources.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

Read the full study on journals.lww.com →

Discuss this study in the Community →

Similar research 5

Appendix A: Mathematical Model AL/RC/ASE. Functional Androgen Axis (FOA) - Operational Version v1.2 Zenodo (CERN European Organization for Nuclear Research) · 2026
Appendix A: Mathematical Model AL/RC/ASE. Functional Androgen Axis (FOA) - Operational Version v1.2 Zenodo (CERN European Organization for Nuclear Research) · 2026
Abstracts Congenital Anomalies · 2016
Selected Abstracts From The 47th Meeting Of The Irish Endocrine Society Sligo, 24th And 25th November 2023 Irish Journal of Medical Science (1971 -) · 2024
Polymer Conjugated Retinoids for Controlled Transdermal Delivery Journal of controlled release · 2017

Related Community Posts Join

6 / 1000+ results

community AH-001 another topical AR degrader beside GT20029, completed Phase I

8 upvotes 10 months ago

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

community HopeMed (Hmi115) is pissed at Absci (Abs-201)

4 upvotes 3 weeks ago

HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.

community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting

in Chat 30 upvotes 5 months ago

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

community Pp405 AAD presentation tomorrow - fingers crossed - what to expect?

in Research/Science 84 upvotes 6 months ago

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

community Black market pp405? Title title

in Treatment 8 upvotes 8 months ago

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march

30 upvotes 6 months ago

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.